Wednesday / June 18. 2025
menu-logo menu-logo
brand-logo
Subscribe
Subscribe
Wednesday / June 18. 2025
  • Read
    • Daily News
      • Financial
      • Insights
      • U.S.
      • International
    • Digital Issue
    • Executive Announcements
    • Cover Stories
    • Feature Articles
      • Exclusive Interviews
    • International Focus
    • Company Spotlights
    • Forward Thinking
    • Legal Briefs
    • Insights from the Outside
    • For You | For Your Field
    • Working Smart
  • Listen & Watch
    • Direct Approach Podcast
    • SHIFT podcast
    • The DSN Podcast
  • Attend
    • DSU Fall 2025
  • Achieve
    • Global 100 List
    • Bravo Awards
    • Best Places to Work
    • Legends
  • Research
    • Stock Watch
    • The DSN Guide
    • Supplier Directory
    • Stock Ticker
    • Resources
  • Engage
    • Supporter Program
    • VIP Text Alerts
  • About
    • About DSN
    • Subscribe
    • Advertise
    • Connect
  • Search
Subscribe

4Life Publishes Research in Medical Journal

BY DSN Staff Writer | November 10, 2021 | read / Daily News / U.S.

4Life’s Research & Development department recently published its scientific research in the Journal of Immunological Methods in the form of a manuscript detailing “method development for the analysis of PBMC-mediated killing of K562 cells by bovine colostrum.” 

“Two years ago, our research was referenced at an Immunology Conference,” said Lead Scientist and Researcher Anna Andersen. “To see our efforts published now in such a reputable journal is deeply satisfying.” 

This study began in 2019 and utilized a technique called flow cytometry to study Natural Killer cells in the immune system and how these cells are affected by bovine colostrum. 

“What an achievement,” said Chief Science Officer Dr. David Vollmer. “Anna Andersen has been with this study since the beginning, and we’re so happy for her and the whole team. It’s rewarding to read about our star ingredient, 4Life Transfer Factor, in a third-party publication. This research will serve as a platform for us to continue our immune system research in the future.”

Posted in Daily News, U.S. and tagged 4Life, Anna Andersen, research and development.
Related Articles
DSA Issues Advocacy Alert Concerning Delaware Bill May 27, 2025

DSA Issues Advocacy Alert Concerning Delaware Bill

Read more
Significant Developments in Avon Products Bankruptcy Proceedings March 07, 2025

Significant Developments in Avon Products Bankruptcy Proceedings

Read more
Plexus Receives US Patent for Immune + March 06, 2025

Plexus Receives US Patent for Immune +

Read more
brand-logo
The News You Need.
The Name You Trust.
Subscribe

Breaking global news, emerging trends and powerful stories conveniently curated to help direct selling executives stay informed, engaged and a step ahead.

  • Read
  • Listen & Watch
  • Attend
  • Achieve
  • Research
  • About
  • Connect
5717 Legacy Drive
Suite 250
Plano, Texas 75024
info@directsellingnews.com
Copyright 2025 Direct Selling News | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Advertise
  • Subscribe
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT